Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that its wholly owned subsidiary, Designer Diagnostics, Inc., will be featured in an upcoming article published in the International Journal of TB and Lung Diseases. The article, which is authored by leading NonTuberculous Mycobacterium (NTM) research scientist, Dr. Rahul Narang, will cover Designer Diagnostics’ paraffin culture technology to isolate NTM.
“The International Journal of TB and Lung Diseases is an important and well-respected publication covering all topics related to lung health,” explained Neil Roth, President of Designer Diagnostics. “This article will act as an important stepping-stone in helping to build awareness about the importance of the Designer Diagnostics technology to isolate NTM,” he added.
Recently, Dr. Narang presented the Designer Diagnostics test kit technology at the 38th Union World Conference on Lung Health in South Africa. Dr. Narang’s presentation included information about the Designer Diagnostics test kits use in isolating NTM from clinical samples of 300 AIDS patients. The presentation also announced that for the first time ever on the Indian subcontinent, M. wolinskyi, a rapidly growing mycobacteria that is most commonly seen in post-traumatic wound infections and in immune-compromised patients, was successfully isolated in clinical samples.
“NTM infection is a serious health issue affecting millions of people each year in developing countries. Especially those countries with high incidence rates of HIV,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We believe that the Designer Diagnostics test kits are vital for early diagnosis of the infection in patients, as the test kits are faster and less expensive than current tests. These kits are perfect for developing countries as they can be used in the field without the need for refrigeration and expensive lab equipment,” he concluded.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The upcoming article in the International Journal of TB and Lung Diseases should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.